Warfarin therapy in a patient homozygous for the CYP2C9*3 allele

Israel Medical Association Journal

Volumn 4, Issue 2, 2002, Pages 139-141

  Ablin, Jacob ^a   Cabili, Shaltiel ^a   Lagziel, Ayala ^a   Peretz, Hava ^a  

^a TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

Author keywords

Anticoagulation; CYP2C9 genotype; Pharmacogenetics; Warfarin

Indexed keywords

ACETYLSALICYLIC ACID; CYTOCHROME P450 2C9; ENALAPRIL; FAMOTIDINE; FUROSEMIDE; VERAPAMIL; WARFARIN;

AGED; ALLELE; ANTICOAGULATION; ARTICLE; BLEEDING; CASE REPORT; CONGESTIVE HEART FAILURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MONITORING; DRUG WITHDRAWAL; GENETIC ANALYSIS; GENOTYPE; HEART ATRIUM FIBRILLATION; HOMOZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LUNG CONGESTION; MALE;

AGED; AGED, 80 AND OVER; ALLELES; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; CYTOCHROME P-450 ENZYME SYSTEM; HEART FAILURE, CONGESTIVE; HOMOZYGOTE; HUMANS; MALE; STEROID 16-ALPHA-HYDROXYLASE; STEROID HYDROXYLASES; WARFARIN;

EID: 0036188747     PISSN: 15651088     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (5)

1. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications
2. Influence of cytochrome P-450 CYP2C9 polymorphisms on warfarin sensitivity and risk of over-anticoagulation in patients on long-term treatment
3. 359 allelic variant in the tolbutamide polymorphism
4. Why do patients with atrial fibrillation not receive warfarin?
5. Population pharmacokinetics of racemic warfarin in adult patients